Glenmark expands OTC portfolio with acquisition of Wockhardt’s ANDAs

Glenmark’s acquisition of several ANDAs from Wockhardt represents its continued expansion into the OTC market.
Sandra Levy
Senior Editor
Sandra Levy profile picture

Glenmark is expanding its OTC portfolio.

The company has acquired Wockhardt’s approved ANDAs for famotidine tablets, 10 mg and 20 mg (OTC); cetirizine hydrochloride tablets, 5 mg and 10 mg (OTC); lansoprazole delayed-release capsules, 15 mg (OTC); and olopatadine hydrochloride ophthalmic solution, 0.1% (OTC).

The over-the-counter market has long been an important segment of Glenmark’s portfolio around the world, said Sanjeev Krishan, president of Glenmark Pharmaceuticals USA. Our acquisition of these ANDAs represents the continued expansion of our business into the OTC market here in the United States and our commitment to ensuring patients have access to high quality, affordable medicines.

[Read more FDA grants Glenmark tentative approval for generic Enstilar]

Glenmark’s current portfolio consists of 175 products authorized for distribution in the United States and 48 ANDAs pending approval with the Food and Drug Administration.

In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio, the company said.